Burden of disease from atrial fibrillation in adults from seven countries in Latin America

Luz Cubillos¹
Alexandra Haddad²
Andreas Kuznik³
Joaquin Mould-Quevedo⁴

¹Medical Affairs, Pfizer Inc., New York, NY, USA; ²Gerente Médico Portafolio Cardiovascular, Dirección Médica, Pfizer Mexico, Mexico City, Mexico; ³Global Health Economics and Outcomes Research, Pfizer Inc., New York, NY, USA; ⁴Health Economics and Outcomes Research, Latin America and Primary Care, Pfizer Inc., New York, NY, USA

The affiliations given here are those from at the time the research was done.

Background: While some international studies have published epidemiologic overviews of atrial fibrillation (AF) for the Latin America region, detailed data at the national level are lacking. The aim of this study was to estimate the burden of disease and morbidity associated with AF in adults over 40 years of age in Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Venezuela.

Methods: National health care system databases for each country in the analysis were used to identify cases of AF during 2010 based on ICD-10 codes. Patient comorbidities and treatment patterns in each country were assessed based on available data and extrapolation from relevant published information where local data were incomplete or unavailable. The prevalence of AF in each country was estimated using country-specific, national census data, and assumptions based on a review of the available literature.

Results: Patients in outpatient or hospital care represented over half of the estimated total cases of AF, of whom around 60% were treated as outpatients. Across the seven countries analyzed, 74.5% of AF cases were adults ≥60 years old. However, with increasing age, the proportion of individuals with AF receiving treatment within the national health care systems decreased overall across all seven countries. The most commonly reported comorbidities associated with AF included arterial hypertension (51%–57%), heart failure (14.5%–30%), diabetes (12%–36.5%), and stroke (3%–12.7%).

Conclusion: This epidemiologic survey quantifies the scale of the challenge posed by AF to the various national health care systems in Latin America. Overall, ambulatory patients in the national health care systems carry a high risk of developing a stroke, yet a significant proportion of these patients do not receive appropriate anticoagulant therapy.

Keywords: Latin America, stroke, atrial fibrillation, burden of disease, epidemiology, anticoagulation

Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia, with nonvalvular AF (defined as AF in the absence of rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair) comprising the majority of AF cases.¹ In general, AF is more prevalent among men than women and occurs more frequently among people of advanced age, with the incidence of AF rising from <0.1%/year in patients aged <40 years to approximately 1.5%/year in women and 2%/year in men aged >80 years.² The prevalence of AF is predicted to increase in the coming decades alongside an aging population in the modern world.³,⁴

AF is associated with a 5-fold increased risk of stroke, and one in five strokes are attributed to this arrhythmia.⁵ Stroke risk in AF is dependent on major risk
factors, including prior stroke, transient ischemic attack, thromboembolism, and older age (≥75 years). Vitamin K antagonists (VKAs) reduce stroke risk in patients with AF by approximately two-thirds compared with placebo and by 38% compared with antiplatelet therapy. Although they have since been updated, guidelines available prior to 2010 recommended long-term oral anticoagulation with VKA dose-adjusted to an international normalized ratio between two and three for patients with AF who are at intermediate (CHADS\(_2\) score of 1) and high (CHADS\(_2\) score of ≥2) risk of stroke.\(^7\)\(^8\)

While some international studies have published epidemiologic overviews of AF for the Latin America region,\(^9\) detailed data at the national level are lacking. Local Latin American studies on AF prevalence exist but are small, with data often recorded at a single hospital.\(^10\)\(^–\)\(^12\) National registry studies for some Latin American countries are underway, but published data are not yet available.\(^13\) Though there is lack of data, the large population in Latin America combined with an aging population suggests that the number of patients with AF in the region is likely to be substantial.\(^14\) Data from a global registry study indicates that the rate of AF-related strokes in South America is comparable to that of Western Europe and the US, indicating a similar burden of disease for the region.\(^15\) However, in the same registry, the 1-year mortality risk for patients with AF was almost twice as high.

The objective of the present investigation was to estimate the morbidity resulting from AF in adults over 40 years of age in Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Venezuela, using local databases and information from their respective national health care systems. Where data were unavailable, extrapolations were made based on available data and estimates from the published literature.

**Materials and methods**

**Information from national databases**

Local sources from the different health care systems in each country\(^16\)\(^–\)\(^28\) were used to determine the number of inpatient and outpatient cases of AF (ICD-10: I48) reported up to the year 2010 (values normalized to 2010), distributed by age group (40–49, 50–59, 60–69, 70–79, and ≥80 years of age) and by sex. Where available, data on comorbidities and treatment were obtained from the national health care system databases.

Based on assessment of the ICD-10 codes recorded in the databases, local notification sources did not allow for differential determination of cases of valvular and nonvalvular AF. In addition, comorbidity and patient treatment data were not available for every patient in the national health care system databases. To better estimate morbidity from AF in the selected seven Latin American countries, a literature review was conducted of published epidemiologic data from Latin America and worldwide, with the aim of extrapolating from the available local data.

**Literature review**

A review of the published literature from the last 20 years to May 2011 was performed, focusing on the prevalence of AF in the total population by age group (40–49, 50–59, 60–69, 70–79, and ≥80 years) and by type of AF (valvular or nonvalvular) in the selected Latin American countries. The MEDLINE, HealthSTAR, PsycINFO, Embase, ScienceDirect, Ovid, and Cochrane Library databases were searched for publications in English, as were the INBIOMED and LILACS databases for publications in Spanish and Portuguese. Queries used the following terms: atrial fibrillation, nonvalvular atrial fibrillation, valvular atrial fibrillation, epidemiology, prevalence, and Latin America, with equivalent terms used for the Spanish and Portuguese language searches. For inclusion in the analysis, publications were required to meet the following criteria: local data with the prevalence of AF among the total population, by age group, and by type of AF.

Fifty-two documents were identified in the initial search relating to the following Latin American countries: Mexico (eleven), Brazil (nine), Argentina (twelve), Chile (eight), Colombia (seven), Peru (three), and Venezuela (two). Of these, all but one did not fulfill the original inclusion criteria, primarily because they referenced international systematic reviews and not local information, and were excluded. Only one publication on AF in Mexico met all criteria for inclusion. Owing to the lack of qualifying studies in the medical literature for AF in Latin America, the search was then widened to include publications relating to AF in other geographic areas. Extending the search internationally identified 37 additional publications, nine of which met the modified inclusion criteria. These included publications in the US (five), UK (two), and Spain (two).

A summary of articles identified by the literature search is shown in Figure 1.

**Estimation of AF prevalence**

In the absence of local epidemiologic data, AF prevalence rates obtained from the published literature were used to estimate the prevalence of AF by age group and by type of AF in each of the Latin American countries included in the study. For the selected literature a meta-analysis, using Comprehensive
Meta-analysis Version 2 (Biostat, Inc., Englewood, NJ, USA)\(^{30}\) was carried out with the random effects method to estimate the absolute risk for the prevalence of AF by age group and by type of AF (valvular and nonvalvular). For this combinatorial analysis, studies were assigned weights using the Jared scale for weighting. The estimates of absolute risk were then applied to the data of the total population and corresponding population pyramids of each country to generate country-specific estimates of the prevalence of AF, which would include patients who had AF but were not diagnosed or receiving treatment. Relative weight of each study and 95% confidence intervals were determined. Analyses of heterogeneity and of selection bias were carried out simultaneously (Q-test, \(P\)-value, \(I^2\)-value, and funnel plot). AF cases were proportionately distributed as valvular or nonvalvular in each country according to the results of this meta-analysis. For comorbidities associated with AF, estimates were made based on local medical data and local literature. The main criterion for inclusion of local literature was published studies with data from the local population and not referencing international systematic reviews – similar to the criteria for AF prevalence (though without the requirement for a breakdown by age/type of AF).

Data on treatment were not available for all patients in the national health care databases but were available for a small proportion of them. To identify any relevant treatment trends, data from a few currently treated patients, along with additional information from local publications where available, were extrapolated to estimate the overall proportion of the total population receiving each treatment in each country.\(^{10,31–34}\)

**Results**

The estimated average prevalence of AF across the seven Latin American countries in this study was 1.6%, based on available population data and estimates from the international literature. Table 1 shows the estimated prevalence by age group and among the total population \(\geq 40\) years of age in each country. The data follow a clear trend, with prevalence increasing with age.

Based on data from the individual national health care systems, patients in outpatient or hospital care represented

<table>
<thead>
<tr>
<th>Age group (year)</th>
<th>Argentina</th>
<th>Brazil</th>
<th>Chile</th>
<th>Colombia</th>
<th>Mexico</th>
<th>Peru</th>
<th>Venezuela</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–49</td>
<td>18,573 (0.40%)</td>
<td>103,203 (0.41%)</td>
<td>10,029 (0.40%)</td>
<td>22,970 (0.40%)</td>
<td>59,637 (0.43%)</td>
<td>13,625 (0.41%)</td>
<td>14,104 (0.41%)</td>
</tr>
<tr>
<td>50–59</td>
<td>28,054 (0.71%)</td>
<td>134,117 (0.72%)</td>
<td>13,793 (0.72%)</td>
<td>29,699 (0.72%)</td>
<td>70,332 (0.75%)</td>
<td>16,480 (0.72%)</td>
<td>17,750 (0.72%)</td>
</tr>
<tr>
<td>60–69</td>
<td>65,573 (2.22%)</td>
<td>247,364 (2.26%)</td>
<td>27,426 (2.25%)</td>
<td>55,581 (2.26%)</td>
<td>128,498 (2.34%)</td>
<td>32,034 (2.24%)</td>
<td>34,430 (2.28%)</td>
</tr>
<tr>
<td>70–79</td>
<td>91,639 (4.78%)</td>
<td>271,939 (4.90%)</td>
<td>33,277 (4.86%)</td>
<td>70,250 (4.94%)</td>
<td>148,795 (5.10%)</td>
<td>40,041 (4.90%)</td>
<td>36,766 (4.89%)</td>
</tr>
<tr>
<td>(\geq 80)</td>
<td>77,509 (8.17%)</td>
<td>143,662 (8.26%)</td>
<td>26,257 (8.26%)</td>
<td>48,467 (8.17%)</td>
<td>114,745 (8.48%)</td>
<td>23,935 (8.31%)</td>
<td>21,354 (8.33%)</td>
</tr>
<tr>
<td>All population (\geq 40)</td>
<td>281,348 (1.95%)</td>
<td>900,285 (1.44%)</td>
<td>110,602 (1.68%)</td>
<td>226,967 (1.59%)</td>
<td>522,007 (1.58%)</td>
<td>126,115 (1.55%)</td>
<td>124,404 (1.47%)</td>
</tr>
</tbody>
</table>

**Note:** Estimated from national demographic data and international literature.

**Abbreviation:** AF, atrial fibrillation.

---

**Table 1** Total AF prevalence (cases, %) in seven Latin American countries, by age group

---
over half of the estimated total cases of AF, of whom around 60% were treated as outpatients (Table 2). Across the seven countries analyzed, 74.5% of AF cases were adults ≥60 years old (Argentina, 81.5%; Brazil, 71.4%; Chile, 76.2%; Colombia, 74.5%; Mexico, 72.7%; Peru, 73.8%; and Venezuela, 72.2%), with proportionately more men than women (57.2% versus 42.8%, respectively). Comparing the estimated prevalence of AF in the total population (Table 1) with that by age group (Table 2) showed that, with increasing age, the proportion of individuals with AF receiving treatment within the national health care systems decreased overall across all seven countries. Based on estimates, nonvalvular AF predominated in these countries, accounting for 85.9% of all cases compared with 14.1% of cases attributed to VAF.

AF as the primary diagnosis and reason for medical care is relatively rare, and over 95% of cases across the seven national health care systems analyzed were identified as secondary or tertiary diagnoses, based on clinical findings in relation to other comorbidities such as stroke, hypertension, or heart failure. The most commonly reported comorbidities associated with AF included arterial hypertension (54.3%; range, 51%–57%), heart failure (24.5%; range, 14.5%–30%), diabetes (22.3%; range, 12%–36.5%), and stroke (8.5%; range, 3%–12.7%).

Antithrombotic and anticoagulant treatments received by both inpatients (grouped as unfractionated heparin, low-molecular-weight heparin, and VKA) and outpatients (grouped as VKA, VKA plus acetylsalicylic acid [ASA], VKA plus ASA plus antiplatelets, and no treatment) for each country are summarized in Table 3. In all countries, the majority of outpatients received VKA or VKA plus ASA (66%–75.8%) with the remainder receiving either no treatment (18.3%–24.6%) or triple therapy with warfarin, ASA, and an additional antiplatelet (3.8%–9.6%). As expected, the use of unfractionated heparin was higher in inpatients (53.9%–65.6%) with only a small percentage of inpatients receiving VKA therapy in any country (7.4%–10.4%), and the remainder receiving low-molecular-weight heparin (26.6%–37.1%) – a reflection of the need for the physician to have more strict control over the level of anticoagulation.

### Discussion

In this epidemiologic study, the distribution of cases reflects both an increase in AF among patients ≥60 years of age and a strong association among the elderly, particularly in patients ≥80 years of age – something that has been clearly demonstrated in multiple trials previously. Population distributions for these seven Latin American countries were very similar with respect to estimates of AF prevalence, and there was a clear trend for increased prevalence with increasing age, as seen in other studies. The aging populations in these Latin American countries, combined with the

### Table 2 AF cases in seven Latin American countries, by age group, sex, comorbidity, type of AF, and inpatient status

<table>
<thead>
<tr>
<th>Cases</th>
<th>Argentina</th>
<th>Brazil</th>
<th>Chile</th>
<th>Colombia</th>
<th>Mexico</th>
<th>Peru</th>
<th>Venezuela</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (% of estimated prevalence)</td>
<td>145,557 (51.7%)</td>
<td>480,108 (53.3%)</td>
<td>58,471 (52.9%)</td>
<td>118,724 (52.3%)</td>
<td>279,747 (53.6%)</td>
<td>67,496 (53.5%)</td>
<td>66,066 (53.1%)</td>
</tr>
<tr>
<td><strong>By age group, year (% of estimated prevalence)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40–49</td>
<td>11,285 (60.8%)</td>
<td>62,643 (60.7%)</td>
<td>6,145 (61.3%)</td>
<td>13,863 (60.4%)</td>
<td>36,767 (61.7%)</td>
<td>8,374 (61.5%)</td>
<td>8,539 (60.5%)</td>
</tr>
<tr>
<td>50–59</td>
<td>15,626 (55.7%)</td>
<td>74,623 (55.6%)</td>
<td>7,747 (56.2%)</td>
<td>16,431 (55.3%)</td>
<td>39,747 (56.5%)</td>
<td>9,285 (56.3%)</td>
<td>9,851 (55.5%)</td>
</tr>
<tr>
<td>60–69</td>
<td>37,851 (57.7%)</td>
<td>142,639 (57.7%)</td>
<td>15,860 (58.2%)</td>
<td>31,867 (57.3%)</td>
<td>75,260 (58.6%)</td>
<td>18,705 (58.4%)</td>
<td>19,802 (57.5%)</td>
</tr>
<tr>
<td>70–79</td>
<td>45,473 (49.6%)</td>
<td>134,802 (49.6%)</td>
<td>16,652 (50.0%)</td>
<td>34,625 (49.3%)</td>
<td>74,916 (50.4%)</td>
<td>20,099 (50.2%)</td>
<td>18,178 (49.4%)</td>
</tr>
<tr>
<td>≥80</td>
<td>35,322 (45.6%)</td>
<td>65,401 (45.5%)</td>
<td>12,067 (46.0%)</td>
<td>21,938 (45.3%)</td>
<td>53,057 (46.2%)</td>
<td>11,033 (46.1%)</td>
<td>9,666 (45.4%)</td>
</tr>
<tr>
<td><strong>By sex (% of total treated)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>83,850 (57.6%)</td>
<td>274,816 (57.2%)</td>
<td>33,541 (40.0%)</td>
<td>67,994 (57.3%)</td>
<td>159,235 (56.9%)</td>
<td>38,542 (57.1%)</td>
<td>37,617 (56.9%)</td>
</tr>
<tr>
<td>Female</td>
<td>61,707 (42.4%)</td>
<td>205,292 (42.8%)</td>
<td>24,930 (60.0%)</td>
<td>50,730 (42.7%)</td>
<td>120,512 (43.1%)</td>
<td>28,954 (42.9%)</td>
<td>28,449 (43.1%)</td>
</tr>
<tr>
<td><strong>By comorbidity (% of total treated)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>82,240 (56.5%)</td>
<td>249,656 (52.0%)</td>
<td>33,328 (57.0%)</td>
<td>60,549 (51.0%)</td>
<td>153,861 (55.0%)</td>
<td>36,785 (54.5%)</td>
<td>35,676 (54.0%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>38,281 (26.3%)</td>
<td>76,817 (16.0%)</td>
<td>8,771 (15.0%)</td>
<td>26,119 (22.0%)</td>
<td>78,329 (28.0%)</td>
<td>24,636 (36.5%)</td>
<td>7,928 (12.0%)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>43,667 (30.0%)</td>
<td>96,022 (20.0%)</td>
<td>17,541 (30.0%)</td>
<td>28,494 (24.0%)</td>
<td>83,924 (30.0%)</td>
<td>9,787 (14.5%)</td>
<td>15,195 (23.0%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>18,486 (12.7%)</td>
<td>43,210 (9.0%)</td>
<td>3,508 (6.0%)</td>
<td>8,311 (7.0%)</td>
<td>27,975 (10.0%)</td>
<td>8,100 (12.0%)</td>
<td>1,982 (3.0%)</td>
</tr>
<tr>
<td><strong>By type of AF (% of total treated)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NVAF</td>
<td>125,342 (86.1%)</td>
<td>412,407 (85.9%)</td>
<td>50,391 (86.2%)</td>
<td>102,043 (86.0%)</td>
<td>240,528 (86.0%)</td>
<td>57,991 (85.9%)</td>
<td>56,366 (85.3%)</td>
</tr>
<tr>
<td>VAF</td>
<td>20,215 (13.9%)</td>
<td>67,701 (14.1%)</td>
<td>8,080 (13.8%)</td>
<td>16,681 (14.1%)</td>
<td>39,210 (14.0%)</td>
<td>9,505 (14.1%)</td>
<td>9,700 (14.7%)</td>
</tr>
<tr>
<td><strong>By inpatient status (% of total treated)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *Data from patients diagnosed and treated in the respective national health care systems; *some patients may have had more than one comorbidity.

**Abbreviations:** AF, atrial fibrillation; NVAF, nonvalvular atrial fibrillation; VAF, valvular atrial fibrillation.
increased prevalence of AF in association with increasing age, suggest there will be an increase over time in the overall prevalence of AF, and a similar increase in the expected number of patients with AF. This aging population trend is mirrored elsewhere, and underscores the burden associated with age-related diseases and comorbidities such as AF and stroke.\textsuperscript{39,40} It will be important to ensure that local and national health care systems are prepared to effectively address this expected increase in the prevalence of AF.\textsuperscript{41}

Two studies in the Spanish population identified the risk factors frequently associated with AF, which included cardiovascular disease, hypertension, aging, left ventricular hypertrophy, diabetes, ischemic cardiomyopathy, ventricular dysfunction, and widening of the atrial diameter \(>45\) mm.\textsuperscript{42,43} In this study, hypertension was present in over 50\% of patients with AF, heart failure in 14.5\%–30\%, and diabetes (12\%–36.5\%), and the prevalence of these comorbidities defines the stroke risk for a significant proportion of these patients as high, as assessed by CHADS\textsubscript{2} or CHADS\textsubscript{2}VASc\textsubscript{2}.\textsuperscript{44}

Despite this potentially high stroke risk population, oral anticoagulation with VKA monotherapy as recommended by the guidelines accounted for only 54\% of all outpatient treatment in the countries analyzed. Among hospitalized patients, the data show that a high percentage (21\%) of patients with AF receive no prophylactic treatment for reducing stroke risk. Older patients with AF are at a higher risk of bleeding than younger patients, and this can dissuade physicians from prescribing oral anticoagulation.\textsuperscript{44} While this and other potential reasons, including cost and other issues, might explain the high proportion of patients not receiving anticoagulation, there is no way of positively identifying the reasons from the data available. Additionally, in a significant proportion of cases, warfarin was used in combination with ASA or with dual antiplatelet therapy. While available guidelines for AF treatment in 2010 recommended oral VKA monotherapy, it is possible some patients had additional comorbidities that justified triple therapy, despite the associated increased risk of bleeding. Since the period covered by this study, further guidelines have been published that help to better stratify patients by stroke risk, allowing for identification of both patients who are truly at low risk of stroke, and those who may benefit most from treatment.\textsuperscript{7,45} Recent guidelines have also included the use of oral anticoagulants such as dabigatran, rivaroxaban, and apixaban. These anticoagulants are alternatives to warfarin for thromboprophylaxis that obviate the need for regular coagulation monitoring, and that may be associated with improved efficacy or bleeding profiles in patients with AF.\textsuperscript{7,46} In this context, Ruiz et al performed a prospective study in patients with chronic nonvalvular AF treated at two cardiology outpatient clinics to analyze major events (death, systemic embolism, and severe hemorrhage) by treatment group.\textsuperscript{47} Results from the study showed that 93\% of the non-anticoagulant cases were receiving antiplatelets, of which ASA was used in 92\% of the cases. Labadet et al\textsuperscript{48} conducted another multicenter study, in Argentina, which followed 840 consecutive patients (75\% of whom were \(\geq\)65 years of age) with chronic AF at high risk of stroke, of whom 48.5\% were treated with oral anticoagulants; medical contraindications to anticoagulation existed in only 17.1\% of the patients. Results from this study also showed that 13.7\% of the study sample had a history of embolic events, but only 20\% of these were receiving anticoagulant treatment when the stroke occurred.

### Study limitations

There is a lack of accurate epidemiology data for AF in Latin American countries. As such, the purpose of this analysis was to utilize local data wherever possible and where no local data were available, extrapolate from prevalence in other countries. Therefore, in the absence of local epidemiological studies, estimates for prevalence are currently limited to...
such extrapolations as this one. One strength of this database analysis is the large numbers of patients that were included. However, the different national health care system databases used for this study employ different reporting methods, and equivalent information was not always available across all of them. Therefore, this study extrapolated from the available data using information taken from the published literature. While local publications were used where possible, international data were also used. Treatment distributions, for example, were estimated from both the available data, which included only a proportion of patients, and local publications. Therefore, the treatment patterns identified here should be challenged and corroborated with field research locally.

Although an extensive search of the specialized medical literature in Latin America was carried out, none of the publications found referred to specific epidemiologic data for each country. Estimates for the prevalence of AF generated by this study for the selected Latin American countries were based on patterns of AF seen internationally, but also take into consideration specific risks resulting from the differing population pyramids and comorbidities of each country analyzed. However, owing to population differences, stroke risk estimates based on Western populations may not be directly applicable.49 Indeed, because of variations in other factors associated with each country, even estimates based on similar ethnic populations in other countries may not be directly applicable.50 As more country- and region-specific data become available, further research will be necessary to confirm the conclusions made here using limited data.

Conclusion
The diversity in the populations and comorbidities seen in this study, as well as the known underreporting of strokes, may warrant further study. However, given the high proportion of patients with AF who received no prophylactic therapy for stroke despite available effective treatments, the results of this study highlight a need for increased awareness of AF and the burden of this condition on the Latin American health care system.

Acknowledgments
This study was funded by Pfizer Inc. The authors would like to thank Alfonso Rosado, Lourdes García, and Gerardo Luna from Links and Links (Tlalpan, México DF) for assistance with data acquisition and analysis; and Andy Shepherd and Meredith Kalish at Caudex Medical for medical writing and editorial assistance, both funded by Pfizer Inc.

Disclosure
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. At the time of study, Alexandra Haddad was an employee of Pfizer Mexico, and Luz Cubillos, Andreas Kuznik, and Joaquin Mould-Quevedo were employees of Pfizer Inc. The authors have no further conflicts of interest in this work.

References
Cubillos et al

